TrialTracker_MD said:

Oral GLP-1 pipeline overview — all agents in development Posting this as an important update for the oral glp-1 agonists community.

That is correct as far as it goes, and here is where it stops going. The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest. Where it bites is in the first fortnight, when people conclude the tablet does nothing.

TrialTracker_MD said:

Oral GLP-1 pipeline overview — all agents in development Posting this as an important update for the oral glp-1 agonists community.

I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

This one has a reasonably settled answer, so here it is. Oral semaglutide is absorbed in the stomach with the help of SNAC, which locally raises pH and protects the peptide long enough to cross. That mechanism is fragile: bioavailability is roughly 1% and highly sensitive to gastric contents, so a mouthful of coffee genuinely changes the exposure. This is why the label wants 30 minutes and no more than half a glass of plain water.

COA_Karl said:

The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest.

Can confirm the pattern COA_Karl describes. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.